These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25427730)

  • 21. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review.
    Horikawa M; Miyayama S; Irie T; Kaji T; Arai Y
    AJR Am J Roentgenol; 2015 Oct; 205(4):764-73. PubMed ID: 26397324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
    Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
    J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization.
    Sadick M; Haas S; Loehr M; Elshwi M; Singer MV; Brade J; Schoenberg SO; Diehl SJ
    Onkologie; 2010; 33(1-2):31-7. PubMed ID: 20164659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.
    Qian J; Oppermann E; Tran A; Imlau U; Qian K; Vogl TJ
    World J Gastroenterol; 2016 Jun; 22(21):5042-9. PubMed ID: 27275096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis.
    Nouso K; Kokudo N; Tanaka M; Kuromatsu R; Nishikawa H; Toyoda H; Oishi N; Kuwaki K; Kusanaga M; Sakaguchi T; Morise Z; Kitai S; Kudo M
    Oncology; 2014; 87 Suppl 1():99-103. PubMed ID: 25427740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
    Cabibbo G; Petta S; Maida M; Cammà C
    Dig Dis; 2015 Sep; 33(5):668-74. PubMed ID: 26398633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
    Hsieh MY; Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents.
    Brown DB; Pilgram TK; Darcy MD; Fundakowski CE; Lisker-Melman M; Chapman WC; Crippin JS
    J Vasc Interv Radiol; 2005 Dec; 16(12):1661-6. PubMed ID: 16371533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
    Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL
    Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expert consensus on transarterial chemoembolization refractoriness and subsequent therapies in hepatocellular carcinoma].
    Clinical Guidelines Committee of Chinese College of Interventionalists
    Zhonghua Nei Ke Za Zhi; 2022 Aug; 61(8):860-866. PubMed ID: 35922209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoembolization for unresectable hepatocellular carcinoma in Japan.
    Takayasu K
    Oncology; 2010 Jul; 78 Suppl 1():135-41. PubMed ID: 20616596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
    Erhardt A; Kolligs F; Dollinger M; Schott E; Wege H; Bitzer M; Gog C; Lammert F; Schuchmann M; Walter C; Blondin D; Ohmann C; Häussinger D
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):947-54. PubMed ID: 25173458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.